James J. Loughlin, Director at Edge Therapeutics, Inc. (EDGE), bought 19,625 shares at $11.00 ($80K) on 2015-10-06, disclosed to the SEC on 2015-10-08.
Open-market purchase of $80k EDGE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 12,261 | $0 | 0.0% |
| 2 | $8.60 | 364 | $3K | 3.9% |
| 3 | $11.00 | 7,000 | $77K | 96.1% |
| Total | $4.08 avg | 19,625 | $80K | 100% |
| Filing → |
| CELG | SELL | 2018-03-13 | $1.7M | — | Filing → |
| CELG | SELL | 2017-06-27 | $2.5M | — | Filing → |
| CELG | SELL | 2017-05-02 | $1.1M | — | Filing → |